Poly(ADP-ribose) polymerase, through ribosylation of nuclear proteins, converts DNA damage into intracellular signals that actuate either DNA repair or cell death
The development of inhibitors to Parp is of ever increasing interest in the drug discovery community since they can be used as modulators of DNA repair mediated resistance to cytotoxic cancer therapeutics.
Until now, commercially available Parp assay kits required multiple steps and were time consuming.
Trevigen overcomes these drawbacks with the release of the HT fluorescent homogeneous Parp Inhibition Assay.
The fluorescent assay is based on the consumption of NAD+ in the Parp ribosylation reaction where NAD+ not consumed by Parp is subsequently measured by a cycling reaction in which a highly fluorescent molecule is produced; therefore an increase in signal positively correlates to increased Parp inhibition.
The subject of a Trevigen patent application, it is a simple assay requiring only 1.5 hours from start to finish.
The 96 test assay requires no wash steps, and detects as little as 10% inhibition of Parp activity.
The assay is ideal for the determination of IC 50 values for Parp Inhibitor
